Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients
Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of AUY922, when administered, in combination
with trastuzumab in adult patients with HER2+ advanced gastric cancer, who have received
trastuzumab plus chemotherapy in the first line.